Neglected Tropical Protozoan Diseases: Drug Repositioning as a Rational Option
- PMID: 26881713
- DOI: 10.2174/1568026616666160216154309
Neglected Tropical Protozoan Diseases: Drug Repositioning as a Rational Option
Abstract
Neglected tropical diseases represent a major sanitary problem and a huge economic burden to endemic countries, and are currently expanding to non-endemic countries owing to migration currents. Though long abandoned in the past, recent research on novel therapeutics has already started to show results. Drug repositioning is one of the prominent, more successful strategies to approach the development of new treatments for these diseases. Here we present an overview on the limitations of the current available medications to treat African trypanosomiasis, Chagas disease and Leishmaniasis, along with a review on drug candidates presently undergoing clinical trials and drug candidates identified through drug repositioning initiatives.
Similar articles
-
Exploring the Potential of Natural Products as Antiparasitic Agents for Neglected Tropical Diseases.Curr Top Med Chem. 2024;24(2):89-108. doi: 10.2174/0115680266256963230921061925. Curr Top Med Chem. 2024. PMID: 37842892 Review.
-
Searching for drugs for Chagas disease, leishmaniasis and schistosomiasis: a review.Int J Antimicrob Agents. 2020 Apr;55(4):105906. doi: 10.1016/j.ijantimicag.2020.105906. Epub 2020 Jan 25. Int J Antimicrob Agents. 2020. PMID: 31987883 Review.
-
Antiprotozoal Activity Profiling of Approved Drugs: A Starting Point toward Drug Repositioning.PLoS One. 2015 Aug 13;10(8):e0135556. doi: 10.1371/journal.pone.0135556. eCollection 2015. PLoS One. 2015. PMID: 26270335 Free PMC article.
-
Infectious diseases. Overcoming neglect of kinetoplastid diseases.Science. 2015 May 29;348(6238):974-6. doi: 10.1126/science.aaa3683. Epub 2015 May 28. Science. 2015. PMID: 26023124 No abstract available.
-
High-throughput screening platform for natural product-based drug discovery against 3 neglected tropical diseases: human African trypanosomiasis, leishmaniasis, and Chagas disease.J Biomol Screen. 2015 Jan;20(1):82-91. doi: 10.1177/1087057114555846. Epub 2014 Oct 20. J Biomol Screen. 2015. PMID: 25332350
Cited by
-
Advances in Protozoan Epigenetic Targets and Their Inhibitors for the Development of New Potential Drugs.Pharmaceuticals (Basel). 2023 Apr 4;16(4):543. doi: 10.3390/ph16040543. Pharmaceuticals (Basel). 2023. PMID: 37111300 Free PMC article. Review.
-
Autophagy in protists and their hosts: When, how and why?Autophagy Rep. 2023;2(1):2149211. doi: 10.1080/27694127.2022.2149211. Epub 2023 Mar 9. Autophagy Rep. 2023. PMID: 37064813 Free PMC article.
-
Proteolytic inhibitors as alternative medicines to treat trypanosomatid-caused diseases: experience with calpain inhibitors.Mem Inst Oswaldo Cruz. 2022 Mar 25;117:e220017. doi: 10.1590/0074-02760220017. eCollection 2022. Mem Inst Oswaldo Cruz. 2022. PMID: 35352772 Free PMC article.
-
Repositioning drug strategy against Trypanosoma cruzi: lessons learned from HIV aspartyl peptidase inhibitors.Mem Inst Oswaldo Cruz. 2022 Mar 16;117:e210386. doi: 10.1590/0074-02760210386. eCollection 2022. Mem Inst Oswaldo Cruz. 2022. PMID: 35293428 Free PMC article.
-
Early reduction in PD-L1 expression predicts faster treatment response in human cutaneous leishmaniasis.J Clin Invest. 2021 Nov 15;131(22):e142765. doi: 10.1172/JCI142765. J Clin Invest. 2021. PMID: 34609968 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous